Xponance Inc. Purchases 592 Shares of Zoetis Inc. (NYSE:ZTS)

by · The Markets Daily

Xponance Inc. grew its holdings in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 0.6% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 107,531 shares of the company’s stock after buying an additional 592 shares during the period. Xponance Inc.’s holdings in Zoetis were worth $17,705,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Rakuten Securities Inc. grew its holdings in Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock worth $28,000 after purchasing an additional 166 shares during the period. Navigoe LLC purchased a new stake in shares of Zoetis in the 4th quarter worth approximately $30,000. Cornerstone Planning Group LLC increased its position in Zoetis by 79.3% during the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after buying an additional 88 shares in the last quarter. Murphy & Mullick Capital Management Corp purchased a new position in Zoetis during the fourth quarter valued at $44,000. Finally, Sound Income Strategies LLC boosted its holdings in Zoetis by 141.4% in the first quarter. Sound Income Strategies LLC now owns 280 shares of the company’s stock worth $46,000 after acquiring an additional 164 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Roxanne Lagano sold 652 shares of the company’s stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the sale, the executive vice president directly owned 15,129 shares in the company, valued at $2,571,930. This represents a 4.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.18% of the stock is currently owned by insiders.

Zoetis Price Performance

NYSE ZTS opened at $158.81 on Friday. The stock has a market capitalization of $70.70 billion, a price-to-earnings ratio of 28.51, a PEG ratio of 2.62 and a beta of 0.91. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.74 and a quick ratio of 1.04. The business’s fifty day moving average price is $161.37 and its 200-day moving average price is $161.93.

Zoetis (NYSE:ZTS – Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 55.48% and a net margin of 27.12%. The business had revenue of $2.22 billion for the quarter, compared to analysts’ expectations of $2.20 billion. During the same period last year, the firm posted $1.38 earnings per share. The business’s revenue for the quarter was up 1.4% on a year-over-year basis. On average, equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.26%. The ex-dividend date is Friday, July 18th. Zoetis’s dividend payout ratio is presently 35.91%.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of analyst reports. Stifel Nicolaus cut shares of Zoetis from a “buy” rating to a “hold” rating and dropped their price target for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. UBS Group dropped their target price on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 7th. Finally, Piper Sandler raised their price target on shares of Zoetis from $205.00 to $210.00 and gave the company an “overweight” rating in a research report on Monday, May 12th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Zoetis currently has an average rating of “Buy” and a consensus price target of $212.13.

Check Out Our Latest Research Report on ZTS

Zoetis Company Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Featured Stories